Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.
Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M; GOELAMS Investigators. Kosmider O, et al. Among authors: recher c. Haematologica. 2011 Jul;96(7):1059-63. doi: 10.3324/haematol.2011.040840. Epub 2011 Apr 20. Haematologica. 2011. PMID: 21508122 Free PMC article.
More than ten percent of relapses occur after five years in AML patients with NPM1 mutation.
Bertoli S, Tavitian S, Bérard E, Mansat-De Mas V, Largeaud L, Gadaud N, Rieu JB, Vergez F, Luquet I, Huguet F, Sarry A, Delabesse E, Récher C. Bertoli S, et al. Among authors: recher c. Leuk Lymphoma. 2020 May;61(5):1226-1229. doi: 10.1080/10428194.2019.1706733. Epub 2020 Feb 5. Leuk Lymphoma. 2020. PMID: 32022605 No abstract available.
Large granular lymphocytosis during quizartinib therapy.
Bertoli S, Rieu JB, Récher C, Vergez F. Bertoli S, et al. Among authors: recher c. Br J Haematol. 2020 Apr;189(1):7. doi: 10.1111/bjh.16373. Epub 2020 Mar 12. Br J Haematol. 2020. PMID: 32162314 Free article. No abstract available.
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Bertoli S, et al. Among authors: recher c. Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773. Cancers (Basel). 2020. PMID: 32218221 Free PMC article.
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C. Vergez F, et al. Among authors: recher c. Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174. Cancers (Basel). 2020. PMID: 32384744 Free PMC article.
Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Beziat G, Tavitian S, Bertoli S, Huguet F, Largeaud L, Luquet I, Vergez F, Rieu JB, Bories P, Delabesse E, Récher C. Beziat G, et al. Among authors: recher c. Eur J Haematol. 2020 Sep;105(3):302-307. doi: 10.1111/ejh.13438. Epub 2020 May 25. Eur J Haematol. 2020. PMID: 32452083
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, Luquet I, De Mas V, Filleron T, Cassou M, Sarry A, Fornecker LM, Simand C, Bertoli S, Recher C, Delabesse E. Bories P, et al. Among authors: recher c. PLoS One. 2020 Oct 1;15(10):e0238795. doi: 10.1371/journal.pone.0238795. eCollection 2020. PLoS One. 2020. PMID: 33001991 Free PMC article.
325 results